Navigation Links
Amicus Therapeutics Presents Positive Results From Phase 1 Clinical,Studies of Plicera for Gaucher Disease

known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus is currently conducting Phase 2 clinical trials for its two lead compounds, Amigal(TM) for Fabry disease, and Plicera(TM) for Gaucher disease. The company is currently conducting Phase 1 trials with AT2220 for the treatment of Pompe disease.

CONTACT: Matthew Patterson of Amicus Therapeutics, +1-609-662-2000; or DanBudwick of BMC Communications Group, +1-212-477-9007, Ext. 14

Web site: http://www.clinicaltrials.gov/http://www.amicustherapeutics.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:12/17/2009)... ANGELES, Dec. 17 Instacare Corp. (OTC ... life-saving and life-enhancing prescription drugs and diagnostics and ... and a leading developer and provider of e-health ... products announced today that as part of the ... has determined to add two new Directors and ...
(Date:12/17/2009)... Resources, one of the world,s leading research and ... finds that over 70 percent of surveyed U.S. ... diabetes drugs with novel mechanisms of action versus ... need for additional DPP-IV inhibitors. Both surveyed physicians ... ability and physicians in particular say the most ...
(Date:12/17/2009)... N.J., Dec. 17 BASF ... has approved the use of Aseptrol® S10 - ... industrial facilities, such as, schools, hospitals, government buildings, ... S10 - Tab is based on Chlorine dioxide ... delivers a broad spectrum disinfectant as stated ...
Breaking Medicine Technology:Instacare Corp. Board of Directors Sets Growth Plans for 2010 2Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 2Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 3BASF's Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label 2BASF's Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label 3Valeritas Announces Appointment of New CEO 12391 1Valeritas Announces Appointment of New CEO 12391 2Valeritas Announces Appointment of New CEO 12391 3Researchers determine predicting factors of positive lung cancer diagnoses in chest radiographs 47488 117 million US children live more than an hour away from trauma care 47486 117 million US children live more than an hour away from trauma care 47486 2
... Micromet, Inc.,(Nasdaq: MITI ), a ... treatment of cancer, inflammation and autoimmune,diseases, presented ... American Association,for Cancer Research (AACR) in San ... levels of subcutaneously administered BiTE(R),antibodies(1). BiTE antibodies ...
... Micromet, Inc.,(Nasdaq: MITI ), a ... treatment of cancer, inflammation and autoimmune,diseases, presented ... Association for,Cancer Research (AACR) in San Diego, ... (Herceptin(R); Genentech, Roche),cetuximab (Erbitux(R); Bristol-Myers Squibb, Imclone, ...
Other Medicine Technology:Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study 2Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study 3Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study 4Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study 5Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 2Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 3Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 4Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 5
(Date:12/17/2009)... hired Deirdre Byrne to lead the firm’s Interim Leadership division as ... experience in healthcare consulting, Byrne will assume her duties at B. ... ... 17, 2009 -- B. E. Smith recently hired Deirdre ... president. A seasoned executive with nearly 20 years of experience in ...
(Date:12/17/2009)... 17 Motionsoft, Inc. announced today that ... Industry (PCI) Data Security Standards (DSS) certification, making ... vendors in the health and wellness space that ... Standard is the result of a collaborative effort ... (Visa International, MasterCard Worldwide, American Express, Discover Financial ...
(Date:12/17/2009)... PHILADELPHIA, Dec. 17 The recently opened ... already out in the community in full force this ... Run on December 13th, benefiting the Arthritis Foundation, a ... of arthritis. The event boasted 1,500 attendees, spotlighting LSI,s ... Run is a renowned, national fundraiser and a festive ...
(Date:12/17/2009)... S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null ... cancer. The results regarding the association between GSTM1 and ... CRC were contradictory. However, the majority of previous reports ... association of the GSTM1/GSTT1 null genotype with the risk ... studies with larger numbers of samples. , A ...
(Date:12/17/2009)... 2009) Researchers from the La Jolla Institute for Allergy ... world,s most dangerous infectious diseases tuberculosis, malaria and ... set of projects seeking to make new inroads toward ... received four project awards totaling $18.8 million from the ... of the National Institutes of Health, to fund the ...
Breaking Medicine News(10 mins):Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3Health News:Motionsoft Completes PCI Compliance Certification 2Health News:Laser Spine Institute (LSI) Supports Jingle Bell Run 2Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 2Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 3Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 4Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 5
... Network for Organ Sharing which oversees the U.S. organ transplant ... hospitals that it is assigned to supervise// according to the ... newspaper when it does act, its findings are usually kept ... risks, such as including excessive death rates. ,This ...
... health problems and hurting outdoor-related businesses in Singapore is ... ,The prolonged pall that has enveloped Southeast ... when the northeast monsoon douses the fires raging in ... October prediction. ,Experts said intermittent showers are ...
... In a finding that may provide a scientific basis ... brain injury reduces the level of a protein that// ... activity, in turn, is thought to be an underlying ... who have suffered a traumatic brain injury (TBI). ...
... eating apples this time of year is just for fun ... may want to think again. //Apples and apple juice may ... their diet, finds a collection of recent research studies, the ... Neuroscience annual conference in Atlanta. Researchers G. Bureau and M. ...
... brain chemical dopamine has always been considered as a 'pleasure ... a manner which extols a person or animal for the ... has shown that certain drugs like cocaine and heroin can ... new study from the University of Michigan adds a new ...
... setting up the "Katrina Clinic" at the Astrodome/Reliant Center ... a medical response to disasters //and other large-scale ... the Southern Medical Journal (SMJ), official journal of the ... of Baylor College of Medicine and colleagues relate and ...
Other Medicine News:Health News:Flaws Reported in overview of US organ transplants 2Health News:How Brain Injury Leads to Seizures, Memory Problems 2Health News:Pick Apples for Good Neurological Health, Says New Research 2Health News:Authors Review Astrodome Medical Response to Hurricane Katrina 2Health News:Authors Review Astrodome Medical Response to Hurricane Katrina 3
0.5 mm short 120 degree angled tip with black ebonized shaft. Titanium handle with position reference indicator. Shaft length 52 mm, handle length 100 mm....
The popular Bechert nucleus rotator has been modified to have the shaft angled 10 mm from tip to bend for ease of manipulation of the lens nucleus in the anterior chamber. Round knurled handle....
... Multi-purpose manipulator with broad tip ... the nucleus during phacoemulsification. The ... through the side port incision ... to guide the lens down ...
1.0 mm long 90 degree angled tip with black ebonized shaft. Titanium handle with position reference indicator. Shaft length 52 mm, handle length 100 mm....
Medicine Products: